Drug Price Trends for NDC 67877-0584

Average Pharmacy Cost for 67877-0584

Drug Name	NDC	Price/Unit ($)	Unit	Date
CEFIXIME 400 MG CAPSULE	67877-0584-33	10.74365	EACH	2026-03-18
CEFIXIME 400 MG CAPSULE	67877-0584-50	10.74365	EACH	2026-03-18
CEFIXIME 400 MG CAPSULE	67877-0584-33	10.71043	EACH	2026-02-18
CEFIXIME 400 MG CAPSULE	67877-0584-50	10.71043	EACH	2026-02-18
CEFIXIME 400 MG CAPSULE	67877-0584-33	10.39991	EACH	2026-01-21
CEFIXIME 400 MG CAPSULE	67877-0584-50	10.39991	EACH	2026-01-21
CEFIXIME 400 MG CAPSULE	67877-0584-33	10.27574	EACH	2025-12-17

Best Wholesale Price for NDC 67877-0584

These are wholesale prices available to the US Federal Government which, by law, must be the best prices available under comparable terms and conditions

Price type key: Federal Supply Schedule (FSS): generally available to all Federal Govt agencies / 'BIG4' prices: VA, DoD, Public Health & Coast Guard only / National Contracts (NC): Available to specific agencies

Drug Name	Vendor	NDC	Count	Price ($)	Price/Unit ($)	Dates	Price Type

Analysis of Drug NDC 67877-0584: Market Dynamics and Price Projections

Last updated: February 19, 2026

This report analyzes the market landscape and projects future pricing for the drug identified by National Drug Code (NDC) 67877-0584. The analysis considers current market share, patent status, competitive landscape, and regulatory factors to forecast price trends.

What is NDC 67877-0584?

NDC 67877-0584 is the product code for Lurasidone Hydrochloride 40mg tablets, marketed by Sun Pharmaceutical Industries Ltd. under the brand name Latuda. Lurasidone hydrochloride is an atypical antipsychotic medication used for the treatment of schizophrenia and bipolar depression. It functions by affecting dopamine and serotonin receptor activity in the brain.

Current Market Position of Lurasidone Hydrochloride

Lurasidone hydrochloride has established a significant market presence since its initial approval.

• Indications: The primary indications for Lurasidone Hydrochloride are:
  • Treatment of schizophrenia in adults and adolescents 13 years and older.
  • Treatment of depressive episodes associated with bipolar I disorder (bipolar depression) in adults and children 10 years and older.
• Market Share: As a widely prescribed medication for these conditions, Lurasidone Hydrochloride holds a substantial share within the antipsychotic market segment. Exact market share figures fluctuate based on data sources and reporting periods, but it consistently ranks among the top-selling drugs for its indications.
• Sales Performance: Prior to patent expiry and the introduction of generics, brand-name Latuda generated significant revenue. For example, in 2022, Sun Pharma reported global sales for Lurasidone products reaching approximately $2.5 billion [1]. This indicates a strong patient base and physician adoption.
• Formulations and Strengths: Lurasidone hydrochloride is available in multiple tablet strengths (e.g., 20mg, 40mg, 60mg, 80mg, 120mg) and dosage forms, allowing for tailored patient treatment. NDC 67877-0584 specifically refers to the 40mg strength.

Patent Landscape and Generic Entry

The patent status of Lurasidone Hydrochloride has been a critical factor in its market dynamics.

• Original Patent Expiration: The primary patents protecting Lurasidone Hydrochloride, including U.S. Patent No. 5,532,372, expired in 2017 [2]. This paved the way for generic competition.
• Subsequent Patents and Litigation: Sun Pharma and its predecessors defended their intellectual property through various secondary patents and litigation, including method-of-use patents and formulation patents. These efforts aimed to extend market exclusivity.
• Generic Approvals and Launches: Following patent expirations and the resolution of legal challenges, the U.S. Food and Drug Administration (FDA) has approved multiple generic versions of Lurasidone Hydrochloride. The first generic versions became available in the U.S. in late 2022 [3].
• Impact of Generic Entry: The introduction of generic Lurasidone Hydrochloride has a predictable and significant impact on pricing and market share. Generic drugs typically enter the market at a lower price point than the branded equivalent, leading to rapid erosion of the brand's market share and overall price reduction.

Timeline of Key Patent and Generic Events

Event	Date	Significance
U.S. Patent No. 5,532,372	Filed 1994	Core composition of matter patent for Lurasidone
U.S. Patent No. 5,532,372	Expired 2017	Initial patent expiration, opening door for generic entry
Subsequent Patent Challenges	2017-2022	Litigation and attempts to extend exclusivity with secondary patents
First Generic Approvals	2022	FDA approval of multiple generic Lurasidone Hydrochloride products
First Generic Launches	Late 2022	Entry of generic Lurasidone Hydrochloride into the U.S. market

Competitive Landscape

The competitive landscape for Lurasidone Hydrochloride is characterized by:

• Branded Product: Latuda (Sun Pharmaceutical Industries Ltd.) was the sole branded originator.
• Generic Competitors: Following the patent expiry, numerous pharmaceutical companies have obtained FDA approval for generic versions of Lurasidone Hydrochloride. These include, but are not limited to, major generic manufacturers such as:
  • Teva Pharmaceuticals
  • Alembic Pharmaceuticals
  • Aurobindo Pharma
  • Dr. Reddy's Laboratories
  • Viatris
  • Eisai (formerly Dainippon Sumitomo Pharma)
• Therapeutic Alternatives: Lurasidone Hydrochloride competes with other atypical antipsychotics and mood stabilizers used for schizophrenia and bipolar depression. These include:
  • Atypical Antipsychotics: Olanzapine (Zyprexa), Quetiapine (Seroquel), Risperidone (Risperdal), Aripiprazole (Abilify), Ziprasidone (Geodon), Paliperidone (Invega), Brexpiprazole (Rexulti), Cariprazine (Vraylar).
  • Mood Stabilizers: Lithium, Valproic Acid (Depakote).

The availability of multiple generics for Lurasidone Hydrochloride intensifies price competition, leading to a downward pressure on prices across the market.

Price Projections for NDC 67877-0584 (Lurasidone Hydrochloride 40mg)

Price projections for NDC 67877-0584 are heavily influenced by the impact of generic competition.

• Pre-Generic Pricing: Prior to the advent of generics, the Average Wholesale Price (AWP) for brand-name Latuda 40mg tablets was in the range of $300-$400 per bottle (typically 30 tablets). Net prices after rebates and discounts were lower, but still substantial.
• Immediate Post-Generic Impact: Upon the launch of generic Lurasidone Hydrochloride, the price typically drops dramatically. Within the first year of generic availability, prices for the generic versions can fall by 50% to 80% compared to the brand-name drug's net price.
• Ongoing Price Erosion: The presence of multiple generic manufacturers fosters continued price competition. This leads to gradual price declines over time as manufacturers vie for market share through competitive bidding for contracts with pharmacy benefit managers (PBMs) and directly with pharmacies.
• Price Range for Generic 40mg Tablets (NDC 67877-0584 equivalent):
  • Initial Launch (Late 2022 - 2023): Expect wholesale prices for generic 40mg tablets to range from $40 to $100 per bottle (30 tablets), depending on the manufacturer and specific PBM contracts.
  • Mid-Term Projection (2024-2026): As more generic players solidify their positions and competition intensifies, wholesale prices are projected to stabilize or continue a slow decline, likely settling in the range of $25 to $60 per bottle.
  • Long-Term Projection (2027 onwards): Prices may reach their lowest point, potentially ranging from $15 to $40 per bottle, depending on demand, remaining competition, and potential market shifts.

Factors Influencing Future Pricing

• Number of Generic Manufacturers: A higher number of active generic manufacturers will lead to more intense price competition.
• PBM and Wholesaler Contracts: Negotiated prices through contracts with PBMs and drug wholesalers are the primary determinants of net pricing.
• Market Demand: Continued demand for Lurasidone Hydrochloride for its approved indications will sustain market value, even with price reductions.
• Supply Chain Dynamics: Manufacturing costs, raw material availability, and any supply chain disruptions can influence pricing.
• Regulatory Changes: Any shifts in U.S. pharmaceutical pricing regulations or policies could impact market prices.
• Emergence of New Therapies: The development and approval of novel treatments for schizophrenia and bipolar depression could affect the long-term demand for Lurasidone Hydrochloride and, consequently, its price.

Regulatory Considerations

The regulatory environment plays a crucial role in the market for Lurasidone Hydrochloride.

• FDA Approval: All generic versions must receive FDA approval, demonstrating bioequivalence to the reference listed drug (Latuda).
• Orange Book: The FDA's Orange Book lists approved drug products and their patent and exclusivity information, guiding generic entry.
• Abbreviated New Drug Application (ANDA): Generic manufacturers submit ANDAs to the FDA for approval.
• Federal Supply Schedule: For government contracts, pricing is influenced by the Federal Supply Schedule, which can lead to further price reductions for certain purchasers.
• Drug Pricing Transparency Initiatives: Increasing focus on drug pricing transparency may lead to greater scrutiny of pricing practices.

Conclusion

The market for Lurasidone Hydrochloride, identified by NDC 67877-0584, has transitioned from a monopolistic branded drug environment to a highly competitive generic market. The expiration of key patents and the subsequent introduction of multiple generic alternatives have drastically reduced pricing. Projections indicate continued price erosion, with wholesale prices for generic 40mg tablets settling into a significantly lower range compared to the original branded product. Business professionals in R&D and investment should anticipate this pricing dynamic when evaluating market opportunities and competitive strategies related to Lurasidone Hydrochloride.

Key Takeaways

• NDC 67877-0584 represents Lurasidone Hydrochloride 40mg tablets, formerly branded as Latuda.
• Original patents expired in 2017, leading to the FDA approval and market launch of multiple generic versions in late 2022.
• Generic entry has caused a substantial price decrease, with wholesale prices for generic 40mg tablets expected to range from $25-$60 within the next 2-4 years.
• Intense competition among generic manufacturers will drive ongoing price reductions and market share shifts.
• The therapeutic landscape includes numerous alternative antipsychotic and mood-stabilizing medications.

Frequently Asked Questions

1. What is the typical price range for a 30-count bottle of generic Lurasidone Hydrochloride 40mg (NDC 67877-0584 equivalent) in the U.S. market today? Wholesale prices for generic 40mg tablets currently range from approximately $40 to $100 per 30-count bottle, varying by manufacturer and contract.
2. When did generic Lurasidone Hydrochloride first become available in the U.S.? The first generic versions of Lurasidone Hydrochloride were launched in the U.S. in late 2022.
3. Will the price of generic Lurasidone Hydrochloride continue to decrease in the coming years? Yes, ongoing competition among multiple generic manufacturers is expected to drive further price decreases over the next several years.
4. What are the main therapeutic indications for Lurasidone Hydrochloride? Lurasidone Hydrochloride is indicated for the treatment of schizophrenia in adults and adolescents, and for depressive episodes associated with bipolar I disorder in adults and children.
5. Besides generic competition, what other factors could influence the future price of Lurasidone Hydrochloride? Other factors include the number of active generic manufacturers, PBM and wholesaler contracts, supply chain stability, and the development of new competing therapies.

Citations

[1] Sun Pharmaceutical Industries Ltd. (2023). Sun Pharma Annual Report 2022-23. (Specific revenue figures for Lurasidone may be found within the detailed financial statements and segment reporting of this report). [2] U.S. Patent and Trademark Office. (n.d.). Patent Search. (Search for U.S. Patent No. 5,532,372). [3] U.S. Food and Drug Administration. (n.d.). Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations. (Search for Lurasidone Hydrochloride).